Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
Abstract
Aim. To investigate endothelial dysfunction (ED) in patients with coronary heart disease (CHD), stable effort angina, Functional Class (FC) I-III, as well as to study perindopril potential in ED correction.
Material and methods. The study included 37 CHD patients (22 men, 15 women; mean age 62,2+5,3 years) with FC I-II (n=22) and FC III angina (n=15). The control group included 16 healthy individuals. Fndothelium-dependent vasodilatation (FDVD) of brachial artery (BA) was assessed in reactive hyperemia test at baseline and after 6 weeks of perindopril therapy (8 mg/d); in controls, FDVD was assessed at baseline only.
Results. At baseline, ED was observed in 79 % of CHD patients: in 42 %, as an inadequate vasodilatation effect (< 10 % from the baseline), and in other 37 %, as no BA diameter increase or vasoconstriction. ED was more prevalent in individuals with FC III angina (93 %) than in participants with FC I-II angina (69 %). Perindopril therapy was associated with increased numbers of patients with vasodilatation > 10 % (+9 %)or<10 % (+3,5 %), while the number of participants with vasoconstriction reduced by 12,5 %. The number of ED participants reduced by 26 % and 8 % for FC I-II and FC III, respectively. Among those with FC I-II angina, perindopril treatment was associated with significant increase in BA diameter (+9,8 %; p<0,05), linear and volumic blood flow velocity (from 15,0+1,9 to 41,5+2,1 cm/s (p<0,05) and from 2,1+0,5 to 6,9+0,5 ml/s (p<0,05), respectively).
Conclusion. Adding perindopril (8 mg/d) to standard anti-ischemic therapy was associated with reduced ED, which could be regarded as a vasoprotective perindopril effect.
About the Authors
O. A. Vartanova
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
N. V. Mikhailova
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
T. E. Morozova
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
References
1. Алмазов В.А., Беркович О.А., Симникова М.Ю., и др. Эндотелиальная дисфункция у больных с дебютом ишемической болезни сердца в разном возрасте. Кардиология 2001; 5: 26-9.
2. Малая Л.Т., Корж А.Н., Балковая Л.Б. Эндотелиальная дисфункция при патологии сердечно-сосудистой системы. X.: Торсинг 2000; 432 с.
3. Diet F., Pratt R.E., Berry G.J. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67.
4. Dostal D.E., Baker K.M. The cardiac renin-angiotensin system: conceptual, or aregulator of cardiac function? Circ Res 1999; 85:
5. Задионченко B.C., Адашева Т.В. Дисфункция эндотелия и артериальная гипертония: терапевтические возможности. РМЖ 2002; 10(1): 12-7.
6. Иванова О.В. Эндотелиальная дисфункция -важный этап атеросклеротического поражения сосудов. Тер архив 1997; 6:75-8.
7. Linz W., Werner G., Gohlke P., et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
8. Pieruzzi F., Abassi Z.A., Keiser H.R. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation 1995; 92: 3105-12.
9. Dzau V., Bernstein K., Celermaier D. et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (Suppl. L): 1-20.
10. Абидова К.Р. Влияние патогенетической терапии на функцию эндотелия у пациентов с ишемической болезнью сердца. Укр кардиолог ж 2001; 4: 19-27.
11. Агеев Ф.Т., Овчинников А.Г. Ингибиторы ангиотензинпревращающего фермента в лечении сердечно-сосудистых заболеваний (Квинаприл и эндотелиальная дисфункция). Вопр мед хим 2001; 1: 23-8.
12. Аронов Д.М., Лупанов В.П. Актуальные вопросы лечения стенокардии. Регистр лекарственных средств России. Справочное издание для врачей. Кардиология 2007; 10: 5-15.
13. Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
14. Vogel R.A. Measurement of endothelial function by brachial artery flow-mediated vasodilatation. Am J Cardiol 2001; 88(2A): 31E-4.
15. Gibbons G.H. Mechanisms of vascular remodelling in hypertension -role of autocrine-paracrine vasoactive factors. Curr Opin Nephrology 1995; 4: 189-96.
16. Ferrari R., Guardigli G., Cicchitelli G. et al. Cardioprotection with ACE inhibitors, non-angiotensin II-related mechanisms. Eur Heart J 2000; 2(Suppl. 1): 122-8.
17. Linz W., Werner G., Gohlke P. et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
18. Hornig B., Drexler H. Endothelial function and bradykinin in humans. Drugs 1997; 5: 42-7.
19. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPAstudy). Lancet 2003; 362: 782-8.
20. Chalmers J. Naal, MacMahon S. On behalf of the PROGRESS Management Committee. PROGRESS (Perindopril pROtection aGainst REcurrent Stroke Study): regional characteristic of the study population at baseline. J Hypertens 2002; 18(Suppl. 1): 13-9.
21. Tsuioshi M., Masato T., Hiroaki S. et al. Long-term treatment with perindopril ameliorates Dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacology 2002; 88: 100-7.
Review
For citations:
Vartanova O.A., Mikhailova N.V., Morozova T.E. Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease. Cardiovascular Therapy and Prevention. 2008;7(3):40-45. (In Russ.)
Views:
484
Email this article 
